1
|
Qiang Z, Wan J, Chen X, Wang H. Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review. Transl Cancer Res 2024; 13:3156-3178. [PMID: 38988928 PMCID: PMC11231811 DOI: 10.21037/tcr-24-837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2024] [Accepted: 06/20/2024] [Indexed: 07/12/2024]
Abstract
Background and Objective Hepatocellular carcinoma (HCC) is a highly heterogeneous and aggressive tumor. In recent years, the incidence of HCC has been increasing worldwide. Despite notable advancements in treatment methodologies, the prognosis of HCC patients remains unsatisfactory. ErbB family proteins play important roles in the occurrence, progression, and metastasis of HCC, and their abnormal expression is often closely associated with poor patient prognosis. This article sought to investigate the current status and research progress of ErbB family protein targeted therapy in HCC in recent years to provide a reference for basic research and clinical treatment. Methods We performed a comprehensive, narrative review of the latest literature to define the current progress of ErbB family receptors in HCC in both the pre-clinical and clinical arenas. Key Content and Findings The ErbB family belongs to the tyrosine kinase (TK) receptor family that comprises four members. These members are closely associated with proliferation, cell cycle regulation, and migration during HCC development through multiple signaling pathways. ErbB-targeted therapy has shown tremendous potential and prospects in the treatment of HCC. Conclusions Through in-depth research and the application of ErbB-targeted therapy, broader avenues will be opened for the treatment of HCC and other tumors, leading to more personalized and precise treatment approaches.
Collapse
Affiliation(s)
- Zeyuan Qiang
- Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China
| | - Juan Wan
- West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine/West China School of Nursing, Sichuan University, Chengdu, China
| | - Xiangzheng Chen
- Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China
| | - Haichuan Wang
- Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
2
|
Zhou W, Li X, Zhang B, Peng H, Quan C, Xiao X, Luo M, Huang Y, Xu D, Huang K, Jin Q, Lu S. The long non-coding RNA CCAT1 promotes erlotinib resistance in cholangiocarcinoma by inducing epithelial-mesenchymal transition via the miR-181a-5p/ROCK2 axis. Am J Cancer Res 2024; 14:2852-2867. [PMID: 39005692 PMCID: PMC11236789 DOI: 10.62347/eqdk1844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 05/24/2024] [Indexed: 07/16/2024] Open
Abstract
Cholangiocarcinoma (CCA) is a common malignancy of the digestive system, and its treatment is greatly challenged by rising chemoresistance. Long non-coding RNAs (lncRNAs) have been shown to play critical roles in the development of drug resistance in tumors. However, the role of the lncRNA CCAT1 in erlotinib resistance in CCA remains unclear. In this investigation, we identified CCAT1 as a pivotal factor contributing to erlotinib resistance in CCA. Furthermore, we uncovered that lncRNA CCAT1 modulated epithelial-mesenchymal transition (EMT) through Rho-associated coiled-coil-forming protein kinase 2 (ROCK2), thereby conferring erlotinib resistance upon CCA cells. Mechanistically, we demonstrated that miR-181a-5p interacted with CCAT1 to modulate the expression of ROCK2. Collectively, these findings shed light on the significant role of CCAT1 in the development of erlotinib resistance in CCA. The functional suppression of CCAT1 holds promise in enhancing the sensitivity to erlotinib by reversing EMT through the miR-181a-5p/ROCK2 signaling pathway. These findings provide valuable insights into the mechanisms underlying erlotinib resistance in CCA and the potential strategies for its treatment.
Collapse
Affiliation(s)
- Wei Zhou
- Department of Abdominal Surgery, Jiangxi Cancer HospitalNanchang 330029, Jiangxi, China
- Oncology Teaching and Research Office, The Second Affiliated Hospital of Nanchang Medical CollegeNanchang 330029, Jiangxi, China
- Key Laboratory of Tumor Transformation Medicine, Jiangxi Cancer HospitalNanchang 330029, Jiangxi, China
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Xingquan Li
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Bolin Zhang
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Hong Peng
- Department of Colorectal Surgery, 908th Hospital of Chinese People’s Liberation Army JointNanchang 330029, Jiangxi, China
| | - Chunyang Quan
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Xin Xiao
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Man Luo
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Yanxiao Huang
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Debin Xu
- Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330006, Jiangxi, China
| | - Kai Huang
- Department of Abdominal Surgery, Jiangxi Cancer HospitalNanchang 330029, Jiangxi, China
- Oncology Teaching and Research Office, The Second Affiliated Hospital of Nanchang Medical CollegeNanchang 330029, Jiangxi, China
- Key Laboratory of Tumor Transformation Medicine, Jiangxi Cancer HospitalNanchang 330029, Jiangxi, China
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
| | - Qifang Jin
- Department of Ophthalmology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330006, Jiangxi, China
| | - Shan Lu
- Oncology Teaching and Research Office, The Second Affiliated Hospital of Nanchang Medical CollegeNanchang 330029, Jiangxi, China
- Key Laboratory of Tumor Transformation Medicine, Jiangxi Cancer HospitalNanchang 330029, Jiangxi, China
- Department of General Surgery, Jiangxi Cancer Hospital, Jiangxi Medical College, Nanchang UniversityNanchang 330029, Jiangxi, China
- Department of Gastroenterology and Oncology, Jiangxi Cancer HospitalNanchang 330029, Jiangxi, China
| |
Collapse
|
3
|
Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, Koustas E, Kanavidis P, Prevezanos D, Kouraklis G, Karamouzis MV, Marinos G, Kontzoglou K, Antoniou EA. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review. Int J Mol Sci 2022; 23:ijms232214117. [PMID: 36430594 PMCID: PMC9698799 DOI: 10.3390/ijms232214117] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 11/10/2022] [Accepted: 11/11/2022] [Indexed: 11/17/2022] Open
Abstract
Hepatocellular carcinoma (HCC) remains one of the most common malignancies and the third cause of cancer-related death worldwide, with surgery being the best prognostic tool. Among the well-known causative factors of HCC are chronic liver virus infections, chronic virus hepatitis B (HBV) and chronic hepatitis virus C (HCV), aflatoxins, tobacco consumption, and non-alcoholic liver disease (NAFLD). There is a need for the development of efficient molecular markers and alternative therapeutic targets of great significance. In this review, we describe the general characteristics of HCC and present a variety of targeted therapies that resulted in progress in HCC therapy.
Collapse
Affiliation(s)
- Christos Damaskos
- Renal Transplantation Unit, Laiko General Hospital, 11527 Athens, Greece
- Nikolaos Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Correspondence: ; Tel.: +30-694-846-7790
| | - Nikolaos Garmpis
- Nikolaos Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Dimitrios Dimitroulis
- Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Anna Garmpi
- First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Iason Psilopatis
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt—Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
| | - Panagiotis Sarantis
- Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Evangelos Koustas
- Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Prodromos Kanavidis
- Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | | | - Gregory Kouraklis
- Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Michail V. Karamouzis
- Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Georgios Marinos
- Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Konstantinos Kontzoglou
- Nikolaos Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| | - Efstathios A. Antoniou
- Nikolaos Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
- Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
| |
Collapse
|
4
|
Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022; 31:693-706. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapy options. Since the approval of sorafenib in 2008, no systemic therapy has provided a sustained/robust/survival benefit for patients with advanced HCC until recently. Many initially promising therapies have been trialed, but survival outcomes remained stagnant. As such, knowledge concerning previous treatment failures may help guide further areas of study, as well inform future therapeutic approaches. AREA COVERED This article reviews recent advances in the treatment of HCC. Despite some recent success, many systemic and locoregional therapies have failed to produce significant improvements in outcome. These treatment failures are examined and insight into pathways for future success are discussed. EXPERT OPINION Combination atezolizumab and bevacizumab has changed the landscape of systemic treatment for patients with HCC when it became the first therapy after demonstrating improve outcomes over sorafenib. Clinical trials in patients with advanced HCC have inherent difficulty with challenges to determine if a patient's declining liver function is secondary to disease progression, worsening cirrhosis, or drug toxicity, which may skew results. As we gain more knowledge of underlying genetic alterations behind the pathophysiology of the development of HCC, molecular markers may be identified to assist in predicting which patients would respond to a specific therapy.
Collapse
|
5
|
Patt YZ, Murad W, Fekrazad MH, Baron AD, Bansal P, Boumber Y, Steinberg K, Lee S, Bedrick E, Du R, Lee FC. INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Med 2017; 6:2042-2051. [PMID: 28801995 PMCID: PMC5603839 DOI: 10.1002/cam4.1138] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Revised: 04/02/2017] [Accepted: 06/02/2017] [Indexed: 01/07/2023] Open
Abstract
Hepatocellular Carcinoma (HCC) incidence is increasing in the USA. Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer (BDC). Erlotinib (E) is an EGFR tyrosine kinase inhibitor (TKI) with known activity against both. We sought to evaluate the efficacy of the combination G+O+E. Patients with either of the two diagnosis were treated in a phase II trial. Simons 2 stage design was used. A disease-control rate (DCR), complete response (CR) + partial response (PR)+ stable disease (SD) at 24 weeks of ≤20% and >40% (P0 and P1 of 0.2 and 0.4, respectively) were set as undesirable (null) and desirable results. 26 HCC and 7 BDC patients were accrued. In HCC, 1 PR, 10 SD, and 9 PDs were seen. DCR in HCC was 42%. Among seven (7) patients with BDC, one patient was not evaluable; one achieved a long lasting PR, and five patients had SD and DCR was 86%. Median overall survival (OS) times and progression-free survivals (PFS) were 196 and 149 days in HCC and 238 days and not reached in BDC. PFS at 26 weeks in HCC was 41% and at 21 weeks in BDC was 60%. Grade 3 toxicities in >5% of patients were fatigue (12.9%), neutropenia (9.6%), thrombocytopenia (9.6%), and diarrhea (6.4%). G+O+E exceeded both preset P0a and P1 of the primary objective with a PFS of 41% at 26 weeks for HCC and preliminary BDC data may warrant further investigations.
Collapse
Affiliation(s)
- Yehuda Z. Patt
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
| | - Waheed Murad
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
- University of California Riverside and Kaiser Permanente RiversideMoreno valleyCalifornia
| | - Mohammed H. Fekrazad
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
- City of Hope National Medical CenterDurateCalifornia
| | - Ari D. Baron
- Pacific Hematology Oncology AssociatesSan FranciscoCalifornia
| | - Pranshu Bansal
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
| | - Yanis Boumber
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
- Fox chase cancer centerPhiladelphiaPennsylvania
| | - Kim Steinberg
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
| | - Sang‐Joon Lee
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
- Division of Epidemiology and BiostatisticsDepartment of MedicineUniversity of New MexicoAlbuquerqueNew Mexico
- Cellitron IncProduct analysis divisionIncheonKorea
| | - Ed Bedrick
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
- Division of Epidemiology and BiostatisticsDepartment of MedicineUniversity of New MexicoAlbuquerqueNew Mexico
| | - Ruofei Du
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
- Division of Epidemiology and BiostatisticsDepartment of MedicineUniversity of New MexicoAlbuquerqueNew Mexico
| | - Fa Chyi Lee
- Division of hematology/oncology, Department of medicineUniversity of New Mexico Comprehensive Cancer CenterAlbuquerqueNew Mexico
| |
Collapse
|